SHANGHAI, June 25 (Reuters) - Novo Nordisk's drug Semaglutide has been approved in China for long-term weight management, the company said in a post on an official WeChat account on Tuesday. (Reporting by Andrew Silver; Editing by Jacqueline Wong)
Novo Nordisk says Semaglutide approved for long-term weight management in China
![Reuters logo](/images/reuters.jpg)